Becton, Dickinson and Company Reports 5.4% Revenue Growth in Q3 2026

Becton, Dickinson and Company (BD) reported a revenue increase of 5.4% for the third quarter of fiscal year 2026, totaling $4.983 billion, compared to $4.726 billion in the same period last year. The growth was driven by a 4.1% increase in volume and a 1.0% positive impact from foreign currency fluctuations. However, net income from continuing operations decreased to $451 million, or $1.64 per diluted share, down from $574 million, or $2.00 per diluted share, in the prior year. The decline in profitability was attributed to higher operating costs, including increased selling and administrative expenses, which rose to $1.261 billion from $1.163 billion year-over-year.

In the nine-month period ending June 30, 2026, BD's revenues reached $14.183 billion, up from $13.539 billion in the previous year. The company experienced a notable increase in operating income, which was reported at $904 million, compared to $906 million in the same period last year. The financial results reflect the impact of the spin-off of BD's former Biosciences and Diagnostic Solutions business, which was completed on February 9, 2026, and is now classified as discontinued operations. This strategic move allowed BD to focus on its core medical technology segments, which include Medical Essentials, Connected Care, BioPharma Systems, and Interventional.

Operationally, BD's restructuring efforts have led to a reorganization of its business segments, with the elimination of the Life Sciences segment post-spin-off. The company reported a total employee headcount of approximately 72,000 as of June 30, 2026, reflecting ongoing adjustments to align with its operational strategy. BD's cash and equivalents, along with short-term investments, totaled $864 million at the end of the quarter, bolstered by a $4 billion cash distribution received from the spin-off entity, which was utilized for share repurchases and debt repayments.

Looking ahead, BD anticipates continued growth driven by its strategic priorities of competing, innovating, and delivering within the medical technology market. The company is focused on enhancing its product offerings and expanding its geographic reach, particularly in emerging markets. However, BD also faces challenges from global macroeconomic factors, including inflation, supply chain disruptions, and regulatory pressures, which could impact future performance. The company remains committed to improving operational efficiency and delivering value to shareholders through dividends and share repurchase programs.